

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINTID:SSPTADK01625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 AUG 15 Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 07 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFT now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN searching
NEWS 13 DEC 01 OberBlast single article calcs feature unavailable

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPCR For general information regarding STN implementation of IPCR

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:34:16 ON 08 DEC 2008

=>Testing the current file.... screen

10565979.trn

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Please change to a suitable file and repeat your upload

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

```
=> file reg
FILE 'REGISTRY' ENTERED AT 10:34:43 ON 08 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1
DICTIONARY FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


```
=> d 11
NO L# DEFINED
```

There are no L# queries, structures, or screen sets defined in the current session.

```
=> ....Testing the current file.... screen
```

ENTER SCREEN EXPRESSION OR (END):end

```
=>
Uploading C:\Program Files\Stnexp\Queries\10565979-res.str
```



```

chain nodes :
7 14 15
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
ring/chain nodes :
16 17
chain bonds :
6-7 7-8 11-14 14-15 15-16 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
6-7 7-8 11-12 11-14 14-15 15-16 15-17
exact bonds :
8-9 8-13 9-10 10-11 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 8 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS

```

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d 11

10565979.trn

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 10:35:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5629 TO ITERATE

35.5% PROCESSED 2000 ITERATIONS 6 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 108081 TO 117079
PROJECTED ANSWERS: 91 TO 583

L3 6 SEA SSS SAM L1

=> d scan

10565979.trn

1.3 6 ANIMES REGISTRY COPYRIGHT 2008 ACS on STN
2H 1-Piperidinomethanamide, 4-[(3-chloro-2-(hydroxymethyl)phenyl)amino]-N-5-
quinoxolinyl-
MF C21 H25 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANIMES DO YOU WISH TO SCAN? (1):200

1.3 6 ANIMES REGISTRY COPYRIGHT 2008 ACS on STN
2H 1-Piperidinomethanamide, N-(3-ethyl-9H-carbazol-3-yl)-4-[(phenylalanino)-
MF C27 H30 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1.3 6 ANIMES REGISTRY COPYRIGHT 2008 ACS on STN
2H 1-Piperidinomethanamide, N,N-diethyl-4-[(3-methoxypropyl)phenylamino]-
4-(*o*-diphenyl-
MF C12 H19 N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1.3 6 ANIMES REGISTRY COPYRIGHT 2008 ACS on STN
2H 1-Piperidinomethanamide, 4-[(2-(Hydroxymethyl)-3-methoxyphenyl)amino]-N-(4-
phenylphenyl)-
MF C27 H31 N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LD 6 ANIMES REGISTRY COPYRIGHT 2008 ACS on STN
 2H 1-(3-*p*-isopropenylbenzylamino)-
 N-[1-(1-hydroxyethyl)phenyl]-4-[2-(hydroxymethyl)-1-
 3-methylbutyl]benzylamino]-
 MP: C23 H31 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

LD 6 ANIMES REGISTRY COPYRIGHT 2008 ACS on STN
 2H 1-(3-*p*-isopropenylbenzylamino)-
 4-[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-[1-(1-
 hydroxyethyl)phenyl]-
 MP: C22 H29 F N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANIMES HAVE BEEN SCANNED

10565979.trn

=> s 11 full
FULL SEARCH INITIATED 10:35:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 112731 TO ITERATE

100.0% PROCESSED 112731 ITERATIONS 519 ANSWERS
SEARCH TIME: 00.00.03

L4 519 SEA SSS FUL L1

=> file caplus
FILE 'CPLUS' ENTERED AT 10:36:05 ON 08 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2008 VOL 149 ISS 24
FILE LAST UPDATED: 7 Dec 2008 (20081207/ED)


Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/legal/infopolicy.html>

=> s 14
L5 27 L4

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 27 ANSWERS - CONTINUE? Y/(N):y



1023288-91-0 CAPLUS
1-Piperazineacetamide, N-(4-acetylphenyl)-4-[(3-hydroxyphenyl)amino]- (CA INDEX NAME)




1023288-91-6 CAPLUS
1-Piperazineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(4-hydroxyphenyl)amino]- (CA INDEX NAME)



1023288-91-8 CAPLUS
1-Piperazineacetamide, 4-[(4-hydroxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



1023288-91-9 CAPLUS
1-Piperazineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(2-methoxyphenyl)amino]- (CA INDEX NAME)



1023288-92-0 CAPLUS
1-Piperazineacetamide, N-(4-benzoylphenyl)-4-[(2-methoxyphenyl)amino]- (CA INDEX NAME)



1023288-92-5 CAPLUS
1-Piperazineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[(3-methoxyphenyl)amino]- (CA INDEX NAME)



1023288-92-6 CAPLUS
1-Piperazineacetamide, 4-[(3-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




1023288-92-7 CAPLUS
1-Piperazineacetamide, N-(4-ethylphenyl)-4-[(4-methoxyphenyl)amino]- (CA INDEX NAME)



1023288-92-8 CAPLUS
1-Piperazineacetamide, 4-[(2-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



1023288-92-9 CAPLUS
1-Piperazineacetamide, 4-[(2-methoxyphenyl)amino]-N-(4-quinoliny)- (CA INDEX NAME)




1023288-92-10 CAPLUS
1-Piperazineacetamide, 4-[(2-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




1023288-92-11 CAPLUS
1-Piperazineacetamide, 4-[(2-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



1023288-92-12 CAPLUS
1-Piperazineacetamide, N-(4-benzoylphenyl)-4-[(3-methoxyphenyl)amino]- (CA INDEX NAME)



1023288-92-13 CAPLUS
1-Piperazineacetamide, N-(4-ethyl-9H-carbazol-3-yl)-4-[(4-methoxyphenyl)amino]- (CA INDEX NAME)





1023288-92-14 CAPLUS
1-Piperazineacetamide, 4-[(4-methoxyphenyl)amino]-N-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



1023288-92-15 CAPLUS
1-Piperazineacetamide, N-[4-(ethyl(2-hydroxyethyl)amino)phenyl]-4-[(4-methoxyphenyl)amino]- (CA INDEX NAME)

LS ANSWER 5 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
 2007172141 Document No. 147147472 Preparation of snake inhibitors of
 leukotriene A4 hydrolase for treating inflammatory disorders; Chen,
 Mingz; Clare, Emmanuel Cleme; Arwey, David; Guiford, William; Klin,
 David; Kyriakos Kirkland, Thomas; Kochanchi, J.; Lissner, Jerry; Light,
 David; Liu, Ming; Liu, Ming; Liu, Ming; Liu, Ming; Liu, Ming; Liu, Ming;
 Schering Aktiengesellschaft, Germany; U.S. Pat. Appl. Publ. US
 20070155737 A1 20070705, 10pp. (English). CODEN: USXQ. APPLICATION:
 US 2005-0557329 (English). PRIORITY: US 2005-0557329 (US) 2005-0557329; US
 2006-0554891 200608054.

G1



II

AS This invention is directed to compounds of formula (I) (where $R = 0-4$; $q = 0-2$; R_1 is a substituent on benzene, naphthalene, indole, etc.; R_2 is a CH_2 alkyl, haloalkyl, etc., or form part of a heterocyclic ring; R_3 is a direct bond, $-O-$, substituted straight or branched alkylene chain, etc.; R_4 is a substituent on benzene, naphthalene, indole, etc.; R_5 is a straight or branched alkylene chain, etc.; each R_6 , R_7 , R_8 , R_9 , R_{10} and R_{11} is independently CH_2 alkyl, haloalkyl, etc., or in some cases form part of a heterocyclic ring; R_{12} is a substituent on benzene, naphthalene, indole, etc.; R_{13} is a direct bond, $-O-$, substituted straight or branched alkylene chain, etc.; R_{14} is a substituent on benzene, naphthalene, indole, etc.) described herein, or pharmaceutically acceptable salts, solutes, polymers, emulsion ions, α -oxides or prodrugs thereof which are leukotriene A4 hydrolase inhibitors and which are therefore useful in treating inflammatory disorders; the use of the compounds of the invention and methods of using and preparing the com-

AS plexes of the invention are also disclosed. Example compound II was prepared by reacting hexahydro-3-(4-phenoxyphenyl)-1*E*,1*E*-diazepine-1-acetamide with 4-isocyanobutanoate. Compounds of the invention, when tested in the UPA (U.S. Patent and Trademark Office) leukotriene A4 hydrolase assay, exhibited the ability to inhibit LTA4 hydrolase activity at IC50 values of less than


LS ANSWER 5 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

2T 943793-62-3P. Methyl 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-piperidinyl]amino]benzoate
 [Chemical preparation]; PEP (Preparation); EACT (Reactant or reagent);
 (analog inhibitors of leukotriene A4 hydrolase for treating

inflammatory disorders and other diseases)

ME 943793-39-3P. Methyl 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-

piperidinyl]amino]- methyl ester (CA INDEX NAME)



2T 943793-23-2P. 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-


piperidinyl]amino]benzoic acid and 943793-39-3P
 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-

piperidinyl]amino]benzoic acid 943793-30-9P
 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-

piperidinyl]amino]benzoic acid 943793-31-9P
 4-[[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-

2-Methyl-1-[1-[2-oxo-2-[(4-phenoxyphenyl)amino]ethyl]-4-


2-Methyl-1-[1-[2-




CH₂
CII 144-62-7
CMR C2 H2 O4



RII 849474-11-3 CARLOS
CH 4-(dimethylamino)carboxylic acid,
1-[3-(dimethylamino)-3-oxo-2-phenylpropyl]-4-
[(1-oxo-2-phenylphenylamino)-, methyl ester (CA INDEX NAME)



CH
CII 849474-51-9
CMR C27 H35 N3 O4



CH₂
CII 144-62-7
CMR C2 H2 O4




RII 849474-15-3 CARLOS
CH 4-(dimethylamino)carboxylic acid,
1-[3-(dimethylamino)-3-oxo-2-phenylpropyl]-
4-((1-oxo-2-phenylphenylamino)-, methyl ester (CA INDEX NAME)



RII 849474-55-4 CARLOS
CH 4-(dimethylamino)carboxylic acid,
1-[3-(dimethylamino)-3-oxo-2-phenylpropyl]-
4-((1-oxo-2-phenylphenylamino)-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)


CH
CII 849474-55-3
CMR C28 H37 N3 O4




CH₂
CII 144-62-7
CMR C2 H2 O4



RII 849474-13-3 CARLOS
CH 4-(dimethylamino)carboxylic acid, 1-[3-(dimethylamino)-4-oxo-3-phenylbutyl]-4-
[(1-oxo-2-phenylphenylamino)-, methyl ester (CA INDEX NAME)




CH
CII 849474-13-1
CMR C18 H37 N3 O4




CH₂
CII 144-62-7
CMR C2 H2 O4



RII 849474-17-5 CARLOS
CH 4-(dimethylamino)carboxylic acid, 1-[3-oxo-2-phenyl-7-(phenylamino)propyl]-4-
[(1-oxo-2-phenylphenylamino)-, methyl ester (CA INDEX NAME)




CH
CII 849474-17-5
CMR C31 H35 N3 O4



OH 2

CNH 144-62-7
CNF C2 H2 O4


RN 849474-13-7 CAPLUS

CN 4-(*tert*-butylsulfonylcarboxylic acid, 1-[3-oxo-2-phenyl-3-[(phenylmethyl)amino]propyl]-4-[(1-oxoethyl)phenylamino]-, methyl ester (CA INDEX NAME)


RN 849474-20-0 CAPLUS

CN 4-(*tert*-butylsulfonylcarboxylic acid, 1-[3-oxo-2-phenyl-3-[(phenylmethyl)amino]propyl]-4-[(1-oxoethyl)phenylamino]-, methyl ester, ethanodioate (1:1) (CA INDEX NAME)

CN 1

CNH 849474-13-7
CNF C22 H37 N3 O4


OH 2

CNH 144-62-7
CNF C2 H2 O4RN 849474-23-3 CAPLUS
CN 4-(*tert*-butylsulfonylcarboxylic acid, 1-[3-[(methyl(2-phenylethyl)amino)-3-oxo-2-phenylpropyl]-4-[(1-oxoethyl)phenylamino]-, methyl ester (CA INDEX NAME)


RN 849474-24-4 CAPLUS

CN 4-(*tert*-butylsulfonylcarboxylic acid, 1-[3-[(methyl(2-phenylethyl)amino)-3-oxo-2-phenylpropyl]-4-[(1-oxoethyl)phenylamino]-, methyl ester, ethanodioate (1:1) (CA INDEX NAME)

CN 1

CNH 849474-23-3
CNF C34 H41 N3 O4


OH 2

CNH 144-62-7
CNF C2 H2 O4RN 849474-21-1 CAPLUS
CN 4-(*tert*-butylsulfonylcarboxylic acid, 1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-4-[(1-oxoethyl)phenylamino]-, methyl ester (CA INDEX NAME)


RN 849474-22-2 CAPLUS

CN 4-(*tert*-butylsulfonylcarboxylic acid, 1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-4-[(1-oxoethyl)phenylamino]-, methyl ester, ethanodioate (1:1) (CA INDEX NAME)

CN 1

CNH 849474-21-1
CNF C23 H39 N3 O4

OH 2

CNH 144-62-7
CNF C2 H2 O4RN 849474-25-5 CAPLUS
CN 4-(*tert*-butylsulfonylcarboxylic acid, 4-[(2-furyl)oxoethyl]phenylamino-1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-, methyl ester (CA INDEX NAME)


RN 849474-25-4 CAPLUS

CN 4-(*tert*-butylsulfonylcarboxylic acid, 4-[(2-furyl)oxoethyl]phenylamino-1-[3-oxo-2-phenyl-3-[(2-phenylethyl)amino]propyl]-, methyl ester, ethanodioate (1:1) (CA INDEX NAME)

CN 1

CNH 849474-25-5
CNF C25 H37 N3 O5

15 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CN 2

CII 144-62-7
CINF C2 H2 O4

320 849474-25-7 CAPLUS
CH 4-Piperidinocarboxylic acid, 1-[3-[(4-amino-4-oxobutyl)amino]-3-oxo-2-phenylpropyl]-4-[(11-oxo-2-phenylpropyl)phenylamino]-, methyl ester (CA INDEX NAME)



CN 1

CII 849474-35-7
CINF C23 H32 O4 O5

15 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CN 2

CII 144-62-7
CINF C2 H2 O4

320 849474-29-2 CAPLUS
CH 4-Piperidinocarboxylic acid, 1-[3-[(4-acetyl-1-piperazinyl)-3-oxo-2-phenylpropyl]-4-[(11-oxo-2-phenylpropyl)phenylamino]-, methyl ester (CA INDEX NAME)




320 849474-40-4 CAPLUS
CH 4-Piperidinocarboxylic acid, 1-[3-[(4-acetyl-1-piperazinyl)-3-oxo-2-phenylpropyl]-4-[(11-oxo-2-phenylpropyl)phenylamino]-, methyl ester, ethanediato (1:1) (CA INDEX NAME)

CN 1

CII 849474-29-2
CINF C20 H32 O4 O4


15 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CN 2

CII 144-62-7
CINF C2 H2 O4

320 849474-31-9 CAPLUS
CH 4-Piperidinocarboxylic acid, 1-[3-[(4-morpholinyl)-3-oxo-2-phenylpropyl]-4-[(11-oxo-2-phenylpropyl)phenylamino]-, methyl ester (CA INDEX NAME)



320 849474-38-0 CAPLUS
CH 4-Piperidinocarboxylic acid, 1-[3-[(4-morpholinyl)-3-oxo-2-phenylpropyl]-4-[(11-oxo-2-phenylpropyl)phenylamino]-, methyl ester, ethanediato (1:1) (CA INDEX NAME)


CN 1

CII 849474-37-9
CINF C29 H37 O3 O5

15 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CII 144-62-7
CINF C2 H2 O4

320 849474-41-5 CAPLUS
CH 4-Piperidinocarboxylic acid, 1-[3-[(4-acetyl-1-piperazinyl)-3-oxo-2-phenylpropyl]-4-[(11-oxo-2-phenylpropyl)phenylamino]-, methyl ester (CA INDEX NAME)



320 849474-42-6 CAPLUS
CH 4-Piperidinocarboxylic acid, 1-[3-[(4-acetyl-1-piperazinyl)-3-oxo-2-phenylpropyl]-4-[(11-oxo-2-phenylpropyl)phenylamino]-, methyl ester, ethanediato (1:1) (CA INDEX NAME)

CN 1

CII 849474-41-5
CINF C21 H42 O4 O5

CN 2

CII 144-62-7
CINF C2 H2 O4


15 ANCHOR 9 OF 27 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)



BB 843474-43-7 CAPUS
 CH 4-Piperidinocarboxylic acid, 1-[3-oxo-2-phenyl-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-4-[1-(oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



BB 843474-44-9 CAPUS
 CH 4-Piperidinocarboxylic acid, 1-[3-oxo-2-phenyl-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-4-[1-(oxopropyl)phenylamino]-, methyl ester, ethanesulfonate (1:1) (CA INDEX NAME)
 CH 1
 CH2 843474-45-7
 CHF C2 344 N4 O4



CH 2
 CH2 144-62-7
 CHF C2 H2 O4


15 ANCHOR 9 OF 27 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)

CH 2
 CH2 144-62-7
 CHF C2 H2 O4



BB 843474-47-1 CAPUS
 CH D-Glucitol, 1-deoxy-1-[3-[4-(methoxycarbonyl)-4-[1-(oxopropyl)phenylamino]-1-oxo-2-phenylpropyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



BB 843474-48-2 CAPUS
 CH 4-Piperidinocarboxylic acid, 1-[3-oxo-2-phenyl-3-[4-(4-hydroxyphenylmethyl)amino]-1-oxo-2-phenylpropyl]-4-[1-(oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)


BB 843474-49-3 CAPUS
 CH 4-Piperidinocarboxylic acid, 1-[3-[(2-(4-hydroxyphenylmethyl)amino)-1-oxo-2-phenylpropyl]-4-[1-(oxopropyl)phenylamino]-, methyl ester, ethanesulfonate (1:1) (CA INDEX NAME)
 CH 1

15 ANCHOR 9 OF 27 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)



BB 843474-45-9 CAPUS
 CH D-Glucitol, 1-deoxy-3-[[3-[4-(methoxycarbonyl)-4-[1-(oxopropyl)phenylamino]-1-piperidinyl]-1-oxo-2-phenylpropyl]methylethylamine]- (CA INDEX NAME)


Absolute stereochemistry.



BB 843474-46-0 CAPUS
 CH D-Glucitol, 1-deoxy-3-[[3-[4-(methoxycarbonyl)-4-[1-(oxopropyl)phenylamino]-1-piperidinyl]-1-oxo-2-phenylpropyl]methylethylamine]-, ethanesulfonate (1:1) (salt) (SC1) (CA INDEX NAME)
 CH 1

BB 843474-45-9
 CHF C32 H45 N3 O9

Absolute stereochemistry.



15 ANCHOR 9 OF 27 CAPUS COPYRIGHT 2009 ACS ON STN (Continued)


CH 2
 CH2 144-62-7
 CHF C2 H2 O4



CH 2
 CH2 144-62-7
 CHF C2 H2 O4



BB 843474-50-6 CAPUS
 CH 4-Piperidinocarboxylic acid, 1-[3-oxo-2-phenyl-3-[2-(2-pyridinyl)ethyl]amino]propyl]-4-[1-(oxopropyl)phenylamino]-, methyl ester (CA INDEX NAME)



BB 843474-51-7 CAPUS
 CH 4-Piperidinocarboxylic acid, 3-[3-oxo-2-phenyl-3-[2-(2-pyridinyl)ethyl]amino]propyl]-4-[1-(oxopropyl)phenylamino]-, methyl ester, ethanesulfonate (1:1) (CA INDEX NAME)

CH 1

BB 843474-56-6
 CHF C32 H45 N3 O4



CN 2

CBR 144-62-7

CMF C2 H2 O4



32 849474-62-3 CAPLUS

CN 4-[(1E,3E)-2,4-diphenylbut-2-enyl]phenylamino-3-oxo-2-phenylpropan-1-yl 4-[(1-oxoethyl)phenylamino]-4-[(1-oxoethyl)phenylamino]-, methyl ester (CA INDEX NAME)



32 849474-62-3 CAPLUS

CN 4-[(1E,3E)-2,4-diphenylbut-2-enyl]phenylamino-3-oxo-2-phenylpropan-1-yl 4-[(1-oxoethyl)phenylamino]-4-[(1-oxoethyl)phenylamino]-, methyl ester, ethanesulfonate (1:1) (CA INDEX NAME)

CN 1

CBR 849474-62-5

CMF C2 H2 O4 O6



CN 2

CBR 144-62-7

CMF C2 H2 O4



32 849474-64-2 CAPLUS

CN 1-oxoperidinopropanamide, N-[2-(1H-indol-3-yl)ethyl]-4-(methoxyethyl)-4-[(1-oxoethyl)phenylamino]-a-phenyl- (CA INDEX NAME)



32 849474-65-3 CAPLUS

CN 1-oxoperidinopropanamide, N-[2-(1H-indol-3-yl)ethyl]-4-(methoxyethyl)-4-[(1-oxoethyl)phenylamino]-a-phenyl-, ethanesulfonate (1:1) (CA INDEX NAME)

CN 1

CBR 849474-64-2

CMF C2 H2 O4 O6



CN 2



CN 2

CBR 144-62-7

CMF C2 H2 O4



32 849474-62-3 CAPLUS

CN 4-[(1E,3E)-2,4-diphenylbut-2-enyl]phenylamino-3-oxo-2-phenylpropan-1-yl 4-[(1-oxoethyl)phenylamino]-4-[(1-oxoethyl)phenylamino]-, methyl ester (CA INDEX NAME)



32 849474-62-3 CAPLUS

CN 4-[(1E,3E)-2,4-diphenylbut-2-enyl]phenylamino-3-oxo-2-phenylpropan-1-yl 4-[(1-oxoethyl)phenylamino]-4-[(1-oxoethyl)phenylamino]-, methyl ester, ethanesulfonate (1:1) (CA INDEX NAME)

CN 1

CBR 849474-62-9

CMF C2 H2 O4 O6



32 849474-64-2 CAPLUS

CN 1-oxiperidinopropanamide, N-[2-(1H-indol-3-yl)ethyl]-4-[(1-oxoethyl)phenylamino]-a,4-diphenyl- (CA INDEX NAME)




32 849474-67-3 CAPLUS

CN 1-oxiperidinopropanamide, N-[2-(1H-indol-3-yl)ethyl]-4-[(1-oxoethyl)phenylamino]-a,4-diphenyl-, ethanesulfonate (1:1) (CA INDEX NAME)

CN 1

CBR 849474-66-4

CMF C2 H2 O4



CN 2

CBR 144-62-7

CMF C2 H2 O4

32 849474-65-6 CAPLUS

CN 4-[(1E,3E)-2,4-diphenylbut-2-enyl]phenylamino-3-oxo-2-phenylpropan-1-yl 4-[(1-oxoethyl)phenylamino]-4-[(1-oxoethyl)phenylamino]-, methyl ester (CA INDEX NAME)

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



321 849474-69-2 CAPLUS

1-(1-[(18-indol-3-yl)ethyl]-4-[(1-oxopropyl)phenylamino]-3-oxo-1-phenylpropyl)-1-[(1-oxopropyl)phenylamino]-, methyl ester, ethanedioate (1:1) (CA INDEX NAME)

CN 1

CNS 849474-69-2

CMF C16 242 94 04



CN 2

CNS 144-62-7

CMF C2 82 04




323 849474-70-0 CAPLUS

1-(1-[(18-indol-3-yl)ethyl]-3-methyl-2-oxo-1-[(1-oxopropyl)phenylamino]-3-oxo-1-phenylpropyl)-, (2S,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.

L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



324 849474-72-2 CAPLUS


1-[(18-indol-3-yl)ethyl]-3-methyl-4-[(1-oxopropyl)phenylamino]-a-phenyl-, ethanedioate (1:1), (2R,3S,4S)-rel- (CA INDEX NAME)

CN 1

CNS 849474-71-1

CMF C14 840 94 02

Relative stereochemistry.



CN 2

CNS 144-62-7

CMF C2 82 04



326 849474-74-4 CAPLUS

1-[(18-indol-3-yl)ethyl]-3-methyl-4-[(1-oxopropyl)phenylamino]-a-phenyl-, ethanedioate (1:1), (2R,3S,4S)-rel- (CA INDEX NAME)


L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CN 1

CNS 849474-75-3

CMF C14 840 94 02

Relative stereochemistry.



CN 2

CNS 144-62-7


CMF C2 82 04



328 849474-75-5 CAPLUS

1-[(18-indol-3-yl)ethyl]-3-methyl-4-[(1-oxopropyl)phenylamino]-a-phenyl-, (2S,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



329 849474-77-7 CAPLUS

1-[(18-indol-3-yl)ethyl]-3-methyl-4-[(1-oxopropyl)phenylamino]-a-phenyl-, ethanedioate (1:1), (4S,2S,4S)-rel- (CA INDEX NAME)

CN 1


L5 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CN 2

CNS 144-62-7

CMF C2 82 04

Relative stereochemistry.



CN 2

CNS 144-62-7

CMF C2 82 04



331 849474-79-9 CAPLUS


1-[(18-indol-3-yl)ethyl]-3-methyl-4-[(1-oxopropyl)phenylamino]-a-phenyl-, ethanedioate (1:1), (2S,3S,4S)-rel- (CA INDEX NAME)

CN 1

CNS 849474-78-8

CMF C14 840 94 02

Relative stereochemistry.




CN 2

CNS 144-62-7

15 ANNEX 9 OF 27 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



331 843474-82-2 CAPLUS
 4-*tert*-butylcarboxylic acid,
 1-[3-*exo*-2-phenyl-3-[(2-[(4-phenylmethoxy)-1*H*-inden-3-yl]ethyl)amino]propyl]-4-[(1-oxo-2-phenylphenylamino)-, methyl ester
 (ICA INDEX NM001)




332 843474-83-3 CAPLUS
 4-*tert*-butylcarboxylic acid,
 1-[3-*exo*-2-phenyl-3-[(2-[(4-phenylmethoxy)-1*H*-inden-3-yl]ethyl)amino]propyl]-4-[(1-oxo-2-phenylphenylamino)-, methyl ester, ethanesulfonate (1*l*l) (salt) (ICA INDEX NM001)
 OH 1
 CH3 843474-82-2
 CMR C15 H40 N4 O5



CH 2
 CH3 144-62-7
 CMR C2 H2 O4

15 ANNEX 9 OF 27 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

333 843474-84-7 CAPLUS
 4-*tert*-butylcarboxylic acid, 1-[3-[(2-[(5-hydroxy-1*H*-inden-3-yl)ethyl]amino)-1-oxo-2-phenylpropyl]-4-[(1-oxo-2-phenylphenylamino)-, methyl ester, ethanesulfonate (1*l*l) (salt) (ICA INDEX NM001)
 OH 1
 CH3 843474-84-6
 CMR C15 H40 N4 O5



CH 2
 CH3 144-62-7
 CMR C2 H2 O4



334 843474-84-8 CAPLUS
 4-*tert*-butylcarboxylic acid,
 1-[2-[(1-methyl-1*H*-inden-3-yl)ethyl]amino]-
 4-[(1-oxo-2-phenylpropyl)-4-[(1-oxo-2-phenylphenylamino)-, methyl ester (ICA INDEX NM001)



335 843474-87-3 CAPLUS
 4-*tert*-butylcarboxylic acid,
 1-[2-[(1-methyl-1*H*-inden-3-yl)ethyl]amino]-
 4-[(1-oxo-2-phenylpropyl)-4-[(1-oxo-2-phenylphenylamino)-, methyl ester, ethanesulfonate (1*l*l) (salt) (ICA INDEX NM001)
 OH 1
 CH3 843474-84-8
 CMR C15 H42 N4 O4

15 ANNEX 9 OF 27 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



336 843474-85-5 CAPLUS
 4-*tert*-butylcarboxylic acid, 1-[1-[(2-[(4-hydroxy-1*H*-inden-3-yl)ethyl]amino)-1-oxo-2-phenylpropyl]-4-[(1-oxo-2-phenylphenylamino)-, methyl ester, ethanesulfonate (1*l*l) (salt) (ICA INDEX NM001)

CH 1
 CH3 843474-82-4
 CMR C15 H40 N4 O5




CH 2
 CH3 144-62-7
 CMR C2 H2 O4



337 843474-84-6 CAPLUS
 4-*tert*-butylcarboxylic acid, 1-[3-[(2-[(5-hydroxy-1*H*-inden-3-yl)ethyl]amino)-1-oxo-2-phenylpropyl]-4-[(1-oxo-2-phenylphenylamino)-, methyl ester (ICA INDEX NM001)



15 ANNEX 9 OF 27 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




CH 2
 CH3 144-62-7
 CMR C2 H2 O4



338 843474-88-0 CAPLUS
 4-*tert*-butylcarboxylic acid,
 1-[3-[(2-[(4-hydroxy-1*H*-inden-3-yl)ethyl]amino)-3-*exo*-2-phenylpropyl]-4-[(1-oxo-2-phenylphenylamino)-, methyl ester (ICA INDEX NM001)



339 843474-89-1 CAPLUS
 4-*tert*-butylcarboxylic acid,
 1-[3-[(2-[(4-hydroxy-1*H*-inden-3-yl)ethyl]amino)-3-*exo*-2-phenylpropyl]-4-[(1-oxo-2-phenylphenylamino)-, methyl ester, ethanesulfonate (1*l*l) (salt) (ICA INDEX NM001)
 OH 1
 CH3 843474-87-0
 CMR C15 H40 N4 O4



CH 2



INN: 438474-90-4 CAMES
 CS: 4-piperidinocarboxylic acid,
 1-[1-[(2-(2-aminimidazol-2-yl)ethyl)amino]-3-
 oxo-2-phenylpropyl]-4-[(1-oxoproxy)phenylamino]-, methyl ester [CA
 INDEX:
 NAME]



929 849474-91-5 CAPLOS
 CN 4-Piperidinescarboxylic acid,
 1-[3-[(4-[2-(1H-benzimidazol-2-yl)ethyl]amino)-3-
 oxo-2-phenylpropyl]-(4-(1-oxaspiro[4.5]octan-4-yl)phenylamino)-, methyl ester,
 ethanedisulfide (1:1) (GA INDEX NAME)




$$\text{HO}-\text{C}(=\text{O})-\text{C}(=\text{O})-\text{OH}$$



CRN 144-62-7
CNF C2 R2 04



RR 043474-32-6 CAPLOS
 CH 4-Piperidinocarboxylic acid,
 1-[3-[2-benzyl[b]thien-3-yl ethyl]amino]-3-oxo-
 2-phenylpropyl)-4-(1-oxopropyl)phenylamino]-, methyl ester (CA INDEX
 name)



2H) 043474-33-7 CAPLOS
 CH 4-Fluoridinecarboxylic acid,
 1-[3-[(2-bromo[b]thien-3-ylethyl)amino]-3-oxo-
 2-phenylpropyl]-4-[(1-naphropylphenylamino)-, methyl ester, ethanedioate
 (1:1) (CA INDEX NAME)

CH 1
CBB 849474-32-6
CHP C35 H39 N3 O6 S




CH 2

LS ANSWER 16 OF 27 CARLSON, COPYRIGHT 2008 ACS on STN
2005-283304 Document No. 142351173
7-anino-1,3,4,4-tetrahydroquinoline derivatives as non-peptidic
neuropeptid Y (NPY) Y₂ receptor inhibitors. Carrathers, Nicholas I.;
Chai, Wenying; Dan, Scott L.; Jablonski, Jill A.; Li, Xiaobing
Lovejoy, Timothy J.; Mihali, V. J.; Pacholski, Barbara; Seestrat,
Mark; Youmans, Mark A. (Johnson & Johnson Pharmaceutical Research &
Development, LLC, USA). U.S. Pat. Appl. Publ. US 20050070543 A
20050331.

34 pp. (English). CODEN: USDOCO. APPLICATION: US 2004-949055 20040904.

$$\begin{array}{c}
 \text{Y}^2-\text{Y}^1 \\
 | \quad | \\
 \text{N} \quad \text{C} \\
 | \quad | \\
 \text{R}^3 \quad \text{R}^2 \\
 | \quad | \\
 \text{N} \quad \text{C} \\
 | \quad | \\
 \text{Y}^4-\text{Y}^3 \\
 | \quad | \\
 \text{N} \quad \text{C} \\
 | \quad | \\
 \text{R}^1
 \end{array}$$

Double bond geometry as shown.



722 848951-94-0 CAPLOS
 C91 1-Piperidineacetanide, 4-[(1-acetyl-2,3-dihydro-1H-3-phenyl-2-propen-1-yl)-2,2,2-trifluoroacetate
 CM 1
 C92 848951-93-9
 C93 C14 H18 N4 O3

Double bond geometry as shown

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT

neostigmine.
Synthesis of anides I and sulfonamides such as II is described in Example 1, a multi-step synthesis of 133 HCl, starting from 1-(tert-butylcarboxyphenyl)-4-piperidinone and Me anhydriolate, was given. The anides I and sulfonamides such as II were tested against neuromuscular transmission in the rat (see *Table 1* for representative examples).
I: 44532-12-0; 44532-12-0; 44532-14-6
II: 44532-13-7; 44532-13-7; 44532-17-9
K1: POC (Phenoxycarbonyl activity); H90 (Synthetic preparation); T90 (Therapeutic use); E105 (Biological study); P99F (Preparation); US85 (Use);
Preparation of anides and sulfonamides as components of active
combination

with NPY receptor affinity and 5-HT₂ receptor affinity)
 C9 845525-31-2 CARLOB
 C9 Benzodiazepine, 2-[1-[(2-oxo-2-[(9-oxo-98-fluorophenoxy-3-yl)amino]ethyl)-4-mine]5-methyl-1,3-dihydro-1,4-dihydro-2H-1,4-benzodiazepin-2-one, hydrochloride, (2:1), (±)-, 0.05, (MPK NAME)



piperidinylamino)-, methyl ester, hydrochloride [(+)] (CA INDEX NAME)

LS ANSWER 10 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Chemical structure of compound 2: CC(C(=O)N[C@@H](C)C)N1CCC[C@H]1CC[C@H](C(=O)C=CC2=CC=CC3=C2C(=O)N4CCC[C@H]4C3)C(=O)N5CCC[C@H]5C



15 ANSWER 11 OF 27 CAP108 COPYRIGHT 2008 ACS on STN (Continued)



388 845525-15-7 CAPLUS
 CH 1-Piperazinoneacetamide,
 N-[9-ethyl-9H-carbazol-3-yl]-4-[(2-hydroxymethyl)-
 6-methylphenyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)

1.1.2. wood

(Continued)



328 845525-16-8 CAPCOS
 C21 1-Piperidinacetamide, 4-[2-(Hydroxymethyl)-4-methylphenyl]amino]-N-(3-methoxybenzyl)- (2R,4S)-



322 845525-17-9 CAPLUS
C21 1-Piperidinedacetamide, 4-[(2-hydroxyethyl)-6-methylphenyl]amino)-N-(9-
oxo-3-fluoro-2-yl)-
ICA INDEX NAME)




222 845525-18-Q CAPLOS
C21 1-(2-*p*-*tert*-butylphenyl)-
N-[2-hydroxy-3-(4-fluorophenyl)-3-yl]-4-[2-(hydroxymethyl)-
4-methylphenyl]amino- (CA INDEX NAME)



380 845525-19-1 CAPL08

15 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
2005:136561 Document No. 142:240311 Preparation of N-carboxylic
1 [phenylalanine]piperidimyl]acetamide derivatives as neuropeptide y5
ligands
2 For the treatment of obesity. Torsten Jover, Antoni Mas Prio, Josep




IT 844642-96-0P, 2-[4-(7-Hydroxy-2-hydroxymethylphenylamino)piperidin-1-yl]-N-(9-methyl-9-oxa-carbazol-3-yl)acetamide 844642-99-7P;


2-[4-(5-Ethyloxy-2-hydroxymethylphenylamino)piperidin-1-yl]-2-(9-methyl-9H-carbazol-3-yl)-acetanide 844642-90-6;

ANSWER 12 OF 27 CAPTION COPYRIGHT 2008 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPM (Synthetic preparation); TBU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
In case of N-methyl-N-[1-(4-aminophenyl)-4-phenylbutyl]benzylamine derivative


1-piperazine-4-aminooxy-1-piperazinecarboxylic acid derivative, a neuropeptide Y ligand for treatment of obesity)
 RS 044642-86-0 CAPLOS
 CN 1-Piperazinecarboxylic acid, 4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]-N-[2-methyl-98-oxybutyl-3-yl]- (CA INDEX NAME)



1-Piperidineacetanide, 4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-(2-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)



1-Piperidinesoctanide, 4-[(5-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-[9-methyl-9H-oxazolo[3-yl)]- (CA INDEX NAME)



CB 1-Piperidin-4-yl-4-[2-hydroxy-6-(hydroxymethyl)phenyl]amino]-N-[3-methyl-9H-carbazol-3-yl]- (CA INDEX NAME)

15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)
 isolated nongp-1 peptide, prep. of phenylmagnesiumbromide and related
 complex, as nonpeptide T5 ligands for the treatment of obesity)
 844442-92-3 CAPLOS
 1-Piperidinasecetamide, N-(3-ethyl-9H-carbaol-3-yl)-4-[(2-hydroxy-2-
 (hydroxymethyl)phenyl)amino]- (CA INDEX NAME)



25 844442-92-3 CAPLOS
 1-Piperidinasecetamide, N-(3-ethyl-9H-carbaol-3-yl)-4-[(2-hydroxy-2-
 (hydroxymethyl)phenyl)amino]- (CA INDEX NAME)



35 844442-95-1 CAPLOS
 1-Piperidinasecetamide, N-(3-ethyl-9H-carbaol-3-yl)-4-[(2-hydroxy-2-
 (hydroxymethyl)phenyl)amino]- (CA INDEX NAME)



45 844442-13-3 CAPLOS
 1-Piperidinasecetamide, 4-[(2-(hydroxymethyl)-4-methylphenyl)amino]-N-
 phenyl- (CA INDEX NAME)




15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)

55 845523-13-1 CAPLOS
 1-Piperidinasecetamide,
 N-(2-hydroxy-9H-fluoren-3-yl)-4-[(2-(hydroxymethyl)-
 6-methylphenyl)amino]- (CA INDEX NAME)




65 845523-25-3 CAPLOS
 1-Piperidinasecetamide,
 4-[(2-(hydroxymethyl)phenyl)amino]-N-3-quinolinyl-
 (CA INDEX NAME)




75 845523-25-6 CAPLOS
 1-Piperidinasecetamide,
 4-[(2-(hydroxymethyl)phenyl)amino]-N-8-quinolinyl-
 (CA INDEX NAME)

15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)

85 845523-14-6 CAPLOS
 1-Piperidinasecetamide, N-(2,3-dihydro-1H-inden-5-yl)-4-[(2-
 (hydroxymethyl)phenyl)amino]- (CA INDEX NAME)



95 845523-16-8 CAPLOS
 1-Piperidinasecetamide, 4-[(2-(hydroxymethyl)-4-methylphenyl)amino]-N-(9-
 oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




105 845523-17-9 CAPLOS
 1-Piperidinasecetamide, 4-[(2-(hydroxymethyl)-6-methylphenyl)amino]-N-(9-
 oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




115 845523-18-0 CAPLOS
 1-Piperidinasecetamide,
 N-(9-hydroxy-9H-fluoren-3-yl)-4-[(2-(hydroxymethyl)-
 4-methylphenyl)amino]- (CA INDEX NAME)


15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)




125 845523-27-7 CAPLOS
 1-Piperidinasecetamide,
 4-[(2-(hydroxymethyl)phenyl)amino]-N-6-quinolinyl-




135 845523-28-0 CAPLOS
 1-Piperidinasecetamide,
 4-[(2-(hydroxymethyl)phenyl)amino]-N-8-quinolinyl-




RU 845553-23-3 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-4-methylphenyl)amino]-N-3-quinoliny-1 (CA INDEX NAME)



RU 845553-20-2 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-4-methylphenyl)amino]-N-5-quinoliny-1 (CA INDEX NAME)



RU 845553-25-2 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-4-methylphenyl)amino]-N-6-quinoliny-1 (CA INDEX NAME)



RU 845553-32-4 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-4-methylphenyl)amino]-N-8-quinoliny-1 (CA INDEX NAME)




RU 845553-33-3 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-6-methylphenyl)amino]-N-3-quinoliny-1 (CA INDEX NAME)




RU 845553-34-6 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-6-methylphenyl)amino]-N-5-quinoliny-1 (CA INDEX NAME)




RU 845553-35-7 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-6-methylphenyl)amino]-N-6-quinoliny-1 (CA INDEX NAME)




RU 845553-36-9 CAPLUS
CN 1-Piperidinemecotanide, 4-[(2-(hydroxymethyl)-6-methylphenyl)amino]-N-8-quinoliny-1 (CA INDEX NAME)



845553-37-9 CARBOS
1-piperidinacetamide, N-(4-benzoylphenyl)-4-[(2-hydroxymethyl)phenyl]amino- (CA INDEX NAME)




845553-38-0 CARBOS
1-piperidinacetamide, N-(4-benzoylphenyl)-4-[(2-hydroxymethyl)-4-methylphenyl]amino- (CA INDEX NAME)



845553-42-6 CARBOS
1-piperidinacetamide, N-(1,3-benzodioxol-5-yl)-4-[(2-hydroxymethyl)-6-methylphenyl]amino- hydrochloride (211) (CA INDEX NAME)




● HCl

845553-43-7 CARBOS
1-piperidinacetamide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-3-quinoxilly- (CA INDEX NAME)




845553-44-8 CARBOS
1-piperidinacetamide, 4-[(4-fluoro-2-(hydroxymethyl)phenyl)amino]-N-3-quinoxilly- (CA INDEX NAME)

845553-45-9 CARBOS
1-piperidinacetamide, 4-[(3-chloro-2-(hydroxymethyl)phenyl)amino]-N-3-quinoxilly- (CA INDEX NAME)





PAGE 1-A




PAGE 2-A






RU 845553-49-3 CAPLUS
CN 1-Piperidinesacetanide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-5-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)


RU 845553-49-2 CAPLUS
1-Piperidinesacetanide, 4-[(3-chloro-2-(hydroxymethyl)phenyl)amino]-N-5-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)




RU 845553-52-4 CAPLUS
CN 1-Piperidinesacetanide, 4-[(4-fluoro-2-(hydroxymethyl)phenyl)amino]-N-5-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)




RU 845553-52-5 CAPLUS
CN 1-Piperidinesacetanide, 4-[(2-(hydroxymethyl)-3-methoxyphenyl)amino]-N-6-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)




RU 845553-52-6 CAPLUS
CN 1-Piperidinesacetanide, 4-[(2-(hydroxymethyl)-3-methoxyphenyl)amino]-N-6-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)



RU 845553-13-9 CAPLUS
CN 1-Piperidinesacetanide, 4-[(4,4-difluoro-2-(hydroxymethyl)phenyl)amino]-N-6-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)




RU 845553-24-5 CAPLUS
CN 1-Piperidinesacetanide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-8-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)



RU 845553-55-0 CAPLUS
CN 1-Piperidinesacetanide, 4-[(4-fluoro-2-(hydroxymethyl)phenyl)amino]-N-8-quinolinyllidine-1-oxepan-2-one
(CA INDEX NAME)




PAGE 1-A





845553-57-3 CAPLUS
CN 1-Piperidinacetamide, N-(4-benzylphenyl)-4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)

PAGE 2-A





845553-58-4 CAPLUS
CN 1-Piperidinacetamide, N-(4-benzylphenyl)-4-[(4-fluoro-2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)



(Continued)




845553-59-1 CAPLUS
CN 1-Piperidinacetamide, 4-[(2-(hydroxymethyl)-6-methoxyphenyl)amino]-N-(4-(hydroxymethyl)phenyl)- (CA INDEX NAME)




845553-62-8 CAPLUS
CN 1-Piperidinacetamide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-(4-(hydroxymethyl)phenyl)- (CA INDEX NAME)




845553-63-9 CAPLUS
CN 1-Piperidinacetamide, 4-[(2-(hydroxymethyl)-4-oxyphenyl)amino]-N-(4-(hydroxymethyl)phenyl)- (CA INDEX NAME)



845553-45-3 CARLOS
1-piperidinacetanide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-[(2-hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)



845553-45-4 CARLOS
1-piperidinacetanide, 4-[(2-(hydroxymethyl)-4-methoxyphenyl)amino]-N-[(2-hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




845553-47-5 CARLOS
1-piperidinacetanide, 4-[(3-chloro-2-(hydroxymethyl)phenyl)amino]-N-[(2-hydroxyphenylmethyl)phenyl]- (CA INDEX NAME)




845553-72-2 CARLOS
1-piperidinacetanide, 4-[(4,5-difluoro-2-(hydroxymethyl)phenyl)amino]-N-[(2-hydroxy-9-fluorene-2-yl)- (CA INDEX NAME)




845553-73-3 CARLOS
1-piperidinacetanide, 4-[(3-chloro-2-(hydroxymethyl)phenyl)amino]-N-[(2-hydroxy-9-fluorene-2-yl)- (CA INDEX NAME)




845553-74-4 CARLOS
1-piperidinacetanide, N-(9-hydroxy-9-fluorene-2-yl)-4-[(2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)



845553-75-5 CARLOS
1-piperidinacetanide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-[(2-hydroxy-9-fluorene-2-yl)- (CA INDEX NAME)



845553-48-6 CARLOS
1-piperidinacetanide, 4-[(2-(hydroxymethyl)phenyl)amino]-N-[(9-oxo-9H-fluorene-2-yl)- (CA INDEX NAME)



845553-49-7 CARLOS
1-piperidinacetanide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-[(9-oxo-9H-fluorene-2-yl)- (CA INDEX NAME)



845553-76-6 CARLOS
1-piperidinacetanide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-[(9-hydroxy-9-fluorene-2-yl)- (CA INDEX NAME)



845553-76-7 CARLOS
1-piperidinacetanide, 4-[(4-chloro-2-(hydroxymethyl)phenyl)amino]-N-[(9-hydroxy-9-fluorene-2-yl)- (CA INDEX NAME)




845553-77-8 CARLOS
1-piperidinacetanide, N-(9-hydroxy-9-fluorene-2-yl)-4-[(2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




845553-78-9 CARLOS
1-piperidinacetanide, 4-[(2-(hydroxymethyl)phenyl)amino]-N-[(9-hydroxy-9-fluorene-2-yl)- (CA INDEX NAME)




845553-79-0 CARLOS
1-piperidinacetanide, 4-[(2-(hydroxymethyl)phenyl)amino]-N-[(9-hydroxy-9-fluorene-2-yl)- (CA INDEX NAME)




821 845553-96-0 CAPLUS
1-Piperidinacetamide, N-(4-acetylphenyl)-4-[(2-hydroxymethyl)-4-nitrophenyl]anilino- (CA INDEX NAME)




821 845553-97-1 CAPLUS
1-Piperidinacetamide, N-(4-acetylphenyl)-4-[(4-fluoro-2-hydroxymethylphenyl)anilino- (CA INDEX NAME)




821 845553-98-2 CAPLUS
1-Piperidinacetamide, N-(4-acetylphenyl)-4-[(2-hydroxymethyl)-6-methoxyphenyl]anilino- (CA INDEX NAME)




821 845554-01-1 CAPLUS
1-Piperidinacetamide, N-[4-[(4-hydroxy-2-hydroxymethylphenyl)anilino]-N-(4-(1-hydroxylethyl)phenyl)- (CA INDEX NAME)




821 845554-03-0 CAPLUS
1-Piperidinacetamide, N-[4-[(4-hydroxy-2-hydroxymethylphenyl)anilino]-N-(4-(1-hydroxylethyl)phenyl)- (CA INDEX NAME)




821 845554-04-1 CAPLUS
1-Piperidinacetamide, N-[4-[(4-fluoro-2-hydroxymethylphenyl)anilino]-N-(4-(1-hydroxylethyl)phenyl)- (CA INDEX NAME)




821 845553-99-3 CAPLUS
1-Piperidinacetamide, N-(4-acetylphenyl)-4-[(3-chloro-2-hydroxymethylphenyl)anilino- (CA INDEX NAME)




821 845554-02-3 CAPLUS
1-Piperidinacetamide, N-[4-(1-hydroxylethyl)phenyl]-4-[(2-hydroxymethylphenyl)anilino- (CA INDEX NAME)




821 845554-03-4 CAPLUS
1-Piperidinacetamide, N-[4-[(1-hydroxylethyl)phenyl]-4-[(2-hydroxymethyl)-6-methoxyphenyl]anilino- (CA INDEX NAME)




821 845554-04-1 CAPLUS
1-Piperidinacetamide, N-[4-[(1-hydroxylethyl)phenyl]-4-[(2-hydroxymethyl)-6-methoxyphenyl]anilino- (CA INDEX NAME)



821 845554-05-0 CAPLUS
1-Piperidinacetamide, N-[4-[(1-hydroxylethyl)phenyl]-4-[(2-hydroxymethyl)-6-methoxyphenyl]anilino- (CA INDEX NAME)




821 845554-07-1 CAPLUS
1-Piperidinacetamide, N-[9-ethyl-9H-carbazol-3-yl]-4-[(2-hydroxymethylphenyl)anilino- (CA INDEX NAME)




845554-24-7 CAPLUS
1-Piperazineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-25-3 CAPLUS
1-Piperazineacetamide, 4-[[4-chloro-3-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-26-5 CAPLUS
1-Piperazineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-30-5 CAPLUS
1-Piperazineacetamide, N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




845554-31-6 CAPLUS
1-Piperazineacetamide, N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




845554-32-7 CAPLUS
1-Piperazineacetamide, N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




845554-33-8 CAPLUS
1-Piperazineacetamide, 4-[[2-(hydroxymethyl)-N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-]amino]- (CA INDEX NAME)




845554-27-0 CAPLUS
1-Piperazineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-28-1 CAPLUS
1-Piperazineacetamide, N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)




845554-29-2 CAPLUS
1-Piperazineacetamide, 4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]-N-(2,3-dihydro-1-oxo-1H-inden-5-yl)- (CA INDEX NAME)



845554-34-9 CAPLUS
1-Piperazineacetamide, N-(2,3-dihydro-1-hydroxy-1H-inden-5-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



845554-35-0 CAPLUS
1-Piperazineacetamide, 4-[[4-bromo-2-(hydroxymethyl)phenyl]amino]-N-(2-ethyl-9H-oxazolabenz-3-yl)- (CA INDEX NAME)




845554-36-1 CAPLUS
1-Piperazineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)



845554-37-2 CAPLUS
1-Piperazineacetamide, 4-[[2-(hydroxymethyl)-4-nethylphenyl]amino]-N-(9-oxo-9H-fluoren-2-yl)- (CA INDEX NAME)



845554-41-3 CAPLUS
1-piperidinacetamide, N-(3-dibenzo[b,f]quinoxolin-4-yl)-4-(2-hydroxymethyl)-6-methoxyphenyl)anilino- (CA INDEX NAME: 845554-41-3)



845554-42-4 CAPLUS
1-piperidinacetamide, N-(3-dibenzo[b,f]quinoxolin-4-yl)-4-(2-hydroxymethyl)-6-methoxyphenyl)anilino- (CA INDEX NAME: 845554-42-4)




845554-43-5 CAPLUS
1-piperidinacetamide, N-(3-dibenzo[b,f]quinoxolin-4-yl)-4-(2-hydroxymethyl)-6-methoxyphenyl)anilino- (CA INDEX NAME: 845554-43-5)




845554-44-6 CAPLUS
1-piperidinacetamide, N-(3-dibenzo[b,f]quinoxolin-4-yl)-4-(2-hydroxymethyl)-6-methoxyphenyl)anilino- (CA INDEX NAME: 845554-44-6)


15 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-6-methoxyphenyl]anilino)-N-(4-phenoxyphenyl)- (CA INDEX NAME: 845554-45-7)




845554-45-7 CAPLUS
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-6-methoxyphenyl]anilino)-N-(4-phenoxyphenyl)- (CA INDEX NAME: 845554-45-7)



845554-46-8 CAPLUS
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-6-methoxyphenyl]anilino)-N-(4-phenoxyphenyl)- (CA INDEX NAME: 845554-46-8)



845554-47-9 CAPLUS
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-6-methoxyphenyl]anilino)-N-(4-phenoxyphenyl)- (CA INDEX NAME: 845554-47-9)



845554-48-0 CAPLUS




845554-49-1 CAPLUS
1-piperidinacetamide, N-(3-dibenzo[b,f]quinoxolin-4-yl)-4-(2-hydroxymethyl)-6-methoxyphenyl)anilino- (CA INDEX NAME: 845554-49-1)



845554-49-2 CAPLUS
1-piperidinacetamide, N-(3-dibenzo[b,f]quinoxolin-4-yl)-4-(2-hydroxymethyl)-6-methoxyphenyl)anilino- (CA INDEX NAME: 845554-49-2)




845554-49-3 CAPLUS
1-piperidinacetamide, N-(3-dibenzo[b,f]quinoxolin-4-yl)-4-(2-hydroxymethyl)-6-methoxyphenyl)anilino- (CA INDEX NAME: 845554-49-3)




845554-49-4 CAPLUS


15 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-3-methoxyphenyl]anilino)-N-(3-quinolino- (CA INDEX NAME: 845554-50-9)



845554-50-9 CAPLUS
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-3-methoxyphenyl]anilino)-N-(3-quinolino- (CA INDEX NAME: 845554-50-9)




845554-51-0 CAPLUS
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-3-methoxyphenyl]anilino)-N-(3-quinolino- (CA INDEX NAME: 845554-51-0)




845554-51-1 CAPLUS
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-3-methoxyphenyl]anilino)-N-(3-quinolino- (CA INDEX NAME: 845554-51-1)




845554-51-2 CAPLUS
1-piperidinacetamide, N-(4-[2-(hydroxymethyl)-3-methoxyphenyl]anilino)-N-(3-quinolino- (CA INDEX NAME: 845554-51-2)




SMILES: 845554-14-3 CAPLUS
1-piperidinacetamide, N-(4-(benzoylphenyl)-4-[(3-hydroxy-2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




SMILES: 845554-54-5 CAPLUS
1-piperidinacetamide, N-(4-(benzoylphenyl)-4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




SMILES: 845554-56-5 CAPLUS
1-piperidinacetamide, N-(4-(benzoylphenyl)-4-[(2-hydroxy-6-(hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




SMILES: 845554-57-6 CAPLUS
1-piperidinacetamide, N-(4-[(2-(hydroxymethyl)-3-methoxyphenyl)amino]-8-(hydroxymethylphenyl)- (CA INDEX NAME)




SMILES: 845554-59-7 CAPLUS
1-piperidinacetamide, N-(4-[(3-hydroxy-2-(hydroxymethyl)phenyl)amino]-8-(4-(hydroxymethylphenyl)phenyl)- (CA INDEX NAME)




SMILES: 845554-60-8 CAPLUS
1-piperidinacetamide, N-(4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-8-(4-(hydroxymethylphenyl)phenyl)- (CA INDEX NAME)




SMILES: 845554-62-1 CAPLUS
1-piperidinacetamide, 6-[(2-hydroxy-5-(hydroxymethyl)phenyl)amino]-8-(4-(hydroxymethylphenyl)phenyl)- (CA INDEX NAME)




SMILES: 845554-64-5 CAPLUS
1-piperidinacetamide, 6-[(2-hydroxy-6-(hydroxymethyl)phenyl)amino]-8-(4-(hydroxymethylphenyl)phenyl)- (CA INDEX NAME)



SMILES: 845554-66-6 CAPLUS
1-piperidinacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[(2-(hydroxymethyl)phenyl)amino]-8-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)




SMILES: 845554-67-7 CAPLUS
1-piperidinacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-8-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)



SMILES: 845554-68-8 CAPLUS
1-piperidinacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[(2-(hydroxymethyl)phenyl)amino]-8-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)





SMILES: 845554-69-9 CAPLUS
1-piperidinacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-8-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)







SMILES: 845554-70-0 CAPLUS
1-piperidinacetamide, N-(9-hydroxy-9H-fluoren-3-yl)-4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-8-(9-oxo-9H-fluoren-3-yl)- (CA INDEX NAME)





15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2008 ACS on STN (Continued)






15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2008 ACS on STN (Continued)




15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2008 ACS on STN (Continued)




15 ANSWER 13 OF 27 CARLOS COPYRIGHT 2008 ACS on STN (Continued)







845554-83-8 CARLOS
1-piperidinacetamide, N-[4-(1-hydroxymethyl)phenyl]-4-[(4-hydroxy-2-(2-hydroxymethyl)phenyl)amino]- (CA INDEX NAME)



845554-87-2 CARLOS
1-piperidinacetamide, N-[4-(1-hydroxymethyl)phenyl]-4-[(2-hydroxy-2-(2-hydroxymethyl)phenyl)amino]- (CA INDEX NAME)




845554-88-0 CARLOS
1-piperidinacetamide,
N-[4-(1-hydroxymethyl)-3-methoxyphenyl]-4-[(2-hydroxymethyl)amino]- (CA INDEX NAME)




845554-89-4 CARLOS
1-piperidinacetamide, 4-[(2-hydroxy-6-(hydroxymethyl)phenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



845554-90-7 CARLOS
1-piperidinacetamide, 4-[(2-(hydroxymethyl)-3-methoxyphenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-91-3 CARLOS
1-piperidinacetamide, 4-[(3-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-92-0 CARLOS
1-piperidinacetamide, 4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-96-2 CARLOS
1-piperidinacetamide, 4-[(2-(hydroxymethyl)-3-methoxyphenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-97-6 CARLOS
1-piperidinacetamide, 4-[(3-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-98-0 CARLOS
1-piperidinacetamide, 4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)




845554-99-2 CARLOS
1-piperidinacetamide, 4-[(2-hydroxy-6-(hydroxymethyl)phenyl)amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)- (CA INDEX NAME)





845554-101-1 CARLOS
1-piperidinacetamide, 4-[(2-(hydroxymethyl)-3-methoxyphenyl)amino]-N-(6-phenoxypyhenyl)- (CA INDEX NAME)



845554-95-2 CARLOS
1-piperidinacetamide, 4-[(3-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-(6-phenoxypyhenyl)- (CA INDEX NAME)



845554-96-3 CARLOS
1-piperidinacetamide, 4-[(4-hydroxy-2-(hydroxymethyl)phenyl)amino]-N-(6-phenoxypyhenyl)- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
phenoxypyhenyl)- (CA INDEX NAME)R5 84554-97-4 CAPLUS
CH 1-Piperidinacetamide, 4-[(2-hydroxy-6-(hydroxymethyl)phenyl)amino]-3-(4-phenoxyphenyl)- (CA INDEX NAME)R5 84554-98-5 CAPLUS
CH 1-Piperidinacetamide,
D-[(2-ethyl-9H-carbazol-3-yl)-4-[(2-(hydroxymethyl)ethyl)-
4-piperidinyl]amino]- (CA INDEX NAME)R5 84554-99-6 CAPLUS
CH 1-piperidinacetamide, 2-[(2-oxo-2-[(9-oxo-9H-fluoren-3-yl)amino]ethyl)-4-
piperidinyl]amino]-, methyl ester (CA INDEX NAME)L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
R5 84555-73-1 CAPLUS
CH 1-Piperidinacetamide, 4-[(2-hydroxy-6-(hydroxymethyl)phenyl)amino]-3-(4-phenoxyphenyl)- (CA INDEX NAME)R5 84555-73-1-7P 8455525-11-7P
KL PAC (Pharmacological activity); SMN (Synthetic preparation); TNO (Therapeutic use); BSC (Biological study); PRMP (Preparation); UDS (Uses); (preparation of phenylaminopiperidinylacetamides and related compds.)

R5 neuropeptide Y1 ligands for the treatment of obesity)




R5 8455525-12-4P 8455525-11-7P
KL PAC (Pharmacological activity); SMN (Synthetic preparation); TNO (Therapeutic use); BSC (Biological study); PRMP (Preparation); UDS (Uses); (preparation of phenylaminopiperidinylacetamides and related compds.)R5 Benzoxazole, 2-[(2-oxo-2-[(9-oxo-9H-fluoren-3-yl)amino]ethyl)-4-
piperidinyl]amino]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

● R51

R5 8455525-13-7 CAPLUS
CH 1-Piperidinacetamide,
D-[(2-ethyl-9H-carbazol-3-yl)-4-[(2-(hydroxymethyl)-
6-oxo-2-phenyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

● R2 HCl




L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

R5 84555-74-2 CAPLUS
CH 1-Piperidinacetamide, 4-[(2-hydroxy-2-(hydroxymethyl)phenyl)amino]-3-(4-phenoxyphenyl)- (CA INDEX NAME)R5 84555-75-3 CAPLUS
CH 1-Piperidinacetamide, 4-[(2-hydroxy-2-(hydroxymethyl)phenyl)amino]-3-(4-phenoxyphenyl)- (CA INDEX NAME)R5 84555-76-4 CAPLUS
CH 1-Piperidinacetamide, 4-[(2-hydroxy-6-(hydroxymethyl)phenyl)amino]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

L5 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)





R5 84555-77-5 CAPLUS

15 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)





335 494058-43-0 CAPLUS
1-Piperidinacetamide, 4-[(4-chlorophenyl)methanino]-N-(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)-a-oxo- (CA INDEX NAME)

15 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(1,2,3,4-tetrahydro-2,3-dioxo-4-quinolinalyl)- (CA INDEX NAME)




340 494058-80-3 CAPLUS
1-Piperidinacetamide, N-(2,3-dihydro-2-oxo-5-benzosoxazolyl)-4-[(methyl(4-nitrophenyl)amino)-a-oxo- (CA INDEX NAME)


15 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



343 494058-85-7 CAPLUS
1-Piperidinacetamide, N-(2,3-dihydro-2-oxo-4-quinolinalyl)- (CA INDEX NAME)





345 494058-87-4 CAPLUS
1-Piperidinacetamide, 4-[(4-chlorophenyl)methanino]-a-oxo-N-(1,2,3,4-tetrahydro-2-oxo-4-quinolinalyl)- (CA INDEX NAME)




347 494058-87-4 CAPLUS
1-Piperidinacetamide, 4-[(4-chlorophenyl)methanino]-a-oxo-N-(1,2,3,4-tetrahydro-2-oxo-4-quinolinalyl)- (CA INDEX NAME)

15 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(Me(4-phenylphenyl)amino)- (CA INDEX NAME)




350 494058-83-4 CAPLUS
1-Piperidinacetamide, N-(2,3-dihydro-2-oxo-1H-indazol-5-yl)-4-[(methyl(4-phenylphenyl)amino)-a-oxo- (CA INDEX NAME)




352 494058-84-5 CAPLUS
1-Piperidinacetamide, N-(2,3-dihydro-2-oxo-1H-indazol-5-yl)-4-[(methyl(4-phenylphenyl)amino)-a-oxo- (CA INDEX NAME)


15 ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)




RI 494055-82-4 CAPLUS
C1 1-Piperidinacetamide, 6-[methyl(4-methylphenyl)amino]- α -oxo-
(2,3,4-tetrahydro-2-oxo-4-quinolyl)- (CA INDEX NAME)



RI 494055-84-6 CAPLUS
C1 1-Piperidinacetamide, N-(2,3-dihydro-3-oxo-1H-benzimidazol-5-yl)- α -oxo-
(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




RI 494055-86-9 CAPLUS
C1 1-Piperidinacetamide,
6-[(4-methylphenyl)methylamino]-N-(2,3-dihydro-2-oxo-
1H-benzimidazol-5-yl)- α -oxo- (CA INDEX NAME)




RI 494055-88-3 CAPLUS


15 ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)




RI 494055-90-8 CAPLUS
C1 1-Piperidinacetamide,
4-[(4-bromophenyl)methylamino]- α -oxo-
(2,3,4-tetrahydro-2-oxo-4-quinolyl)- (CA INDEX NAME)




RI 494055-92-2 CAPLUS
C1 1-Piperidinacetamide, 6-[(4-bromophenyl)methylamino]- α -oxo-
(2,3,4-tetrahydro-2-oxo-4-quinolyl)- (CA INDEX NAME)




RI 494055-94-6 CAPLUS
C1 1-Piperidinacetamide,
4-[(4-bromophenyl)methylamino]- α -oxo-
(2,3,4-tetrahydro-2-oxo-4-quinolyl)- (CA INDEX NAME)



RI 494055-96-4 CAPLUS
C1 1-Piperidinacetamide,
4-[(4-bromophenyl)methylamino]- α -oxo-
(2,3,4-tetrahydro-2-oxo-4-quinolyl)- (CA INDEX NAME)






15 ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)
C1 1-Piperidinacetamide, 4-[(4-chlorophenyl)methylamino]- α -oxo-
(2,3,4-tetrahydro-2-oxo-4-quinolyl)- (CA INDEX NAME)

RI 494055-97-0 CAPLUS
C1 1-Piperidinacetamide,
6-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-
1H-benzimidazol-5-yl)- α -oxo- (CA INDEX NAME)



RI 494055-98-3 CAPLUS
C1 1-Piperidinacetamide, N-(3,4-dihydro-3-oxo-1H-benzimidazol-5-yl)- α -oxo-
(4-chlorophenyl)methylamino- (CA INDEX NAME)


15 ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)



LS ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)
 CH 436053-22-4 CARLOS
 1-piperidinacetamide,
 4-[(4-chlorophenyl)methylamino]-N-(4-hydroxyphenyl)-
 (CA INDEX NAME)




LS 436053-13-3 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-(4-hydroxyphenyl)- (CA INDEX NAME)



LS 436053-24-6 CARLOS
 1-piperidinacetamide,
 N-(4-hydroxyphenyl)-4-(methylphenylamino)- (CA INDEX NAME)




LS 436053-30-5 CARLOS
 1-piperidinacetamide,
 N-(2-benzimidazol-6-yl)-4-[(4-chlorophenyl)methylamino]- (CA INDEX NAME)




LS 436053-93-7 CARLOS


LS ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)




LS 436053-94-2 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-6-benzothiophenyl)- (CA INDEX NAME)



LS 436053-97-3 CARLOS
 1-piperidinacetamide,
 4-[(4-chlorophenyl)methylamino]-N-1H-Indazol-5-yl- (CA INDEX NAME)




LS 436053-98-4 CARLOS
 1-piperidinacetamide,
 4-[(4-chlorophenyl)methylamino]-N-1H-Indazol-5-yl- (CA INDEX NAME)




LS 436053-99-5 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-1H-Indazol-5-yl- (CA INDEX NAME)

LS ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)
 CH 436053-92-8 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-thieno-6-benzothiophenyl)- (CA INDEX NAME)




LS 436053-92-8 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-thieno-6-benzothiophenyl)- (CA INDEX NAME)




LS 436053-94-0 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-(1,3,2,4-tetrahydro-2-oxo-4-phenylazolyl)- (CA INDEX NAME)


LS ANSWER 15 OF 27 CARLOS COPYRIGHT 2009 ACS on STN (Continued)




LS 436069-00-5 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-(1,2-dimethyl-1H-indol-5-yl)- (CA INDEX NAME)




LS 436069-01-6 CARLOS
 1-piperidinacetamide, 4-[(4-chlorophenyl)methylamino]-N-(2,3-dihydro-2-oxo-6-benzothiophenyl)- (CA INDEX NAME)




LS 436069-16-3 CARLOS
 1-piperidinacetamide, N-(2,3-dihydro-2-oxo-6-benzothiophenyl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




LS 436069-17-4 CARLOS
 1-piperidinacetamide, N-(2,3-dihydro-2-oxo-5-benzothiophenyl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-17-1 CARLOS
1-piperidinacetamide, N-(2-(3-dihydro-2-oxo-1H-indol-5-yl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)



494060-19-1 CARLOS
1-piperidinacetamide, N-(2-(3-dihydro-2-oxo-1H-indol-5-yl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-20-9 CARLOS
1-piperidinacetamide, N-(2-benzimidazol-6-yl-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-21-0 CARLOS
1-piperidinacetamide, N-(3,4-dihydro-2H-1,4-benzodiazin-7-yl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-25-5 CARLOS
1-piperidinacetamide, N-(2-(3-dihydro-2-thioxo-1H-benzimidazol-5-yl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-27-1 CARLOS
1-piperidinacetamide, N-(2-methyl-1H-indol-5-yl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-28-7 CARLOS
1-piperidinacetamide, 4-[(4-bromophenyl)methylamino]-N-(2-methyl-1H-benzimidazol-6-yl)- (CA INDEX NAME)




494060-29-8 CARLOS




494060-22-1 CARLOS
1-piperidinacetamide, N-(2-(3-dihydro-2-thieno-4-benzothiophenyl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-23-2 CARLOS
1-piperidinacetamide, 4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-24-3 CARLOS
1-piperidinacetamide, 4-(methyl(4-methylphenyl)amino)-" (CA INDEX NAME)



494060-31-2 CARLOS
1-piperidinacetamide, N-(2-methyl-1H-indol-5-yl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-32-3 CARLOS
1-piperidinacetamide, N-(2-methyl-1H-indol-5-yl)-4-(methyl(4-methylphenyl)amino)- (CA INDEX NAME)




494060-33-4 CARLOS


L5 ANSWER 15 OF 27 CAFL05 COPYRIGHT 2009 ACS on STN (Continued)
 CS1 1-piperidinacetamide, 4-[(4-methylphenyl)amino]-
 N-1-indan-6-yl-4-[(4-methylphenyl)amino]-
 (CA INDEX NAME)



RR 494060-34-5 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-1-(2,3-dihydro-2-oxo-1H-inden-5-yl)- (CA INDEX NAME)



RR 494060-35-6 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-1-(2,3-dihydro-2-oxo-1H-inden-5-yl)- (CA INDEX NAME)




RR 494060-36-7 CAFL05
 CS1 1-piperidinacetamide, N-18-benzimidazol-6-yl-4-[(4-bromophenyl)amino]- (CA INDEX NAME)




RR 494060-37-8 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-18-indol-5-yl- (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAFL05 COPYRIGHT 2009 ACS on STN (Continued)
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-18-indol-5-yl- (CA INDEX NAME)




RR 494060-38-9 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-18-indol-5-yl- (CA INDEX NAME)



RR 494060-41-4 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-[(2,3-dihydro-2-thieno-4-benzothiophenyl)- (CA INDEX NAME)




RR 494060-42-3 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-[(2,3-dihydro-2-thieno-4-benzothiophenyl)- (CA INDEX NAME)




RR 494060-43-6 CAFL05
 CS1 1-piperidinacetamide, N-(2-methyl-1H-benzimidazol-5-yl)-4-[(4-methylphenyl)amino]- (CA INDEX NAME)

RR 494060-44-7 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-[(2,3-dihydro-2-oxo-5-methylazepin-1-yl)- (CA INDEX NAME)


L5 ANSWER 15 OF 27 CAFL05 COPYRIGHT 2009 ACS on STN (Continued)



RR 494060-45-8 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-[(2,3-dihydro-2-oxo-5-methylazepin-1-yl)- (CA INDEX NAME)




RR 494060-46-9 CAFL05
 CS1 1-piperidinacetamide, 4-[(4-bromophenyl)amino]-N-[(2,3-dihydro-2-oxo-5-methylazepin-1-yl)- (CA INDEX NAME)




RR 494060-47-0 CAFL05

L5 ANSWER 15 OF 27 CAFL05 COPYRIGHT 2009 ACS on STN (Continued)



RR



37 data were given.
38 432023-32-OP 432023-36-4P
39 432023-32-OP 432023-36-4P


15 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN
2002-72044 Document No. 136:134675 Preparation of heterocyclic amino-
alcohols

(b) A 4-*Ph*-ring substituted with (X)₂N, (c) a biphenyl ring substituted with (X)₂N, or (d) a Ph-fused heterocycle selected from (X)₂N-substituted

or
 a bond; W is O, $\text{Si}(\text{O})_4$, NR_2 , $\text{NC}(\text{O})\text{R}_2$; X is SO_2 , $\text{C}(\text{O})$, $-(\text{CH}_2)_n$, a bond, Ar ;


LS ANSWER 17 OF 27 CAPTION COPYRIGHT 2008 ACS ON STH (Continued)
 (Therapeutic use); EBI (Biological study); CMRI (Combinatorial study);
 PKEP (Preparation); USES (Uses)
 (preparation; high-energy carboxylic acids as lipid lowering agents)
 43200-53-0 C10H14N
 CM 1-Piperidin-4-oxane, N-ethyl- ω -phenyl-4-[(4-[4-(trifluoromethyl)-1,3-bis(2-yl)carbonyl]anisyl)phenyl]amino]- [C]

INDEX NAME)



781 433033-36-4 CNT070

229 432023-36-4 CAPLOS
 C31 1-Piperidinomethanide, α -phenyl-N-propyl-4-[(4-[(4'-
 (trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl)amino]phenylamino]-
 280958 (NOMS) (C)



15 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2000 ACS on STN (Continued)
in the alkyl moiety; R₃ is E; alkyl optionally substituted with

substituents selected from hydroxy, halogen, and aryl; cycloalkyl of 3-6 atoms; Ar, or Het; R12 and R13 are each, independently, *N*, alkyl, or aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R12 and R13 are taken together to form a spiro fused cycloalkyl ring of 3-8 C atoms; R12 and R13 are each, independently, *N*, alkyl of 1-8 C atoms, aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R12 and R13 are taken together with the *N* to which they are attached to form a

3-7
 membered satd. heterocycle, which may optionally contain 1-2 addnl. heterocycles selected from O and S, and said heterocycle may optionally have substituents selected from K14; K12 is COOR1 or aryl optionally substituted with 1-3 substituents selected from -OR15 and cycloalkoxy of 3-6 C atoms;
 K15 is alkyl of 1-8 C atoms or arylalkyl having 1-8 C atoms in the alkyl

moiety. As is an arom. ring system contg. 1-2 carbocyclic aron. rings having 6-10 C atoms optionally mono, di, or tri substituted with R₁; R₂ is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, S, and N which may be optionally mono or disubstituted with R₁ or (b) a heterocyclic ring system optionally mono- or disubstituted by

or
a 5-6 membered heterocyclic ring contg. 1-4 heteroatoms selected from O, S and N. R17, R18, and R19 are each, independently, H, alkyl of 1-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl moiety, or aryl optionally mono, di, or tri-substituted with halogen, cyano, nitro, hydroxy, alkylidene of 1-8 C atoms, or alkoxy of 1-8 C atoms; or when R17 and R18 are contained on a common N, R17 and R18 may be taken together with


the N to which they are attached to form a 3-7 membered satd. heterocycle, which may optionally contain 1-2 addtl. heteroatoms selected from O and S.

$\lambda = 0-2$; $\mu = 1-6$; $\delta = 0-3$; $\epsilon = 1-6$; $\gamma = 1-6$; $\eta = 0-6$; $\nu = 0-6$; $\rho = 0-6$; $\sigma = 0-2$; $\tau = 1-6$; $\zeta = 1-6$. Methods of prepns. are claimed, comprising (a) reacting ACCH_2 -substituted oxirane or a protected form


thereof in which a reactive substituent group is protected, with $\text{HC}(\text{CH}_2\text{CH}_2\text{VC}(\text{CH}_3)_2)_2\text{p}$ or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting

group to give 1 (9 = OCBz_2). (b) reacting Ar' -substituted oxirane or a protected form thereof in which any reactive substituent group is protected, with $\text{H}_2\text{Bz}_2\text{C}(=\text{O})\text{C}_6\text{H}_4\text{Me}-p$ or a protected form thereof in which reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U represents a bond; (c) reacting


or
 a protected form thereof in which a reactive substituent group is
 protected; and if required removing any protecting group to give 1
 wherein
 U = $-\text{OCR}_2-$. (d) reacting $\text{ACN}(\text{OH})\text{CH}_2\text{NH}_2$ or a protected form thereof in
 wherein



22 242360-27-7 CAROLUS
22 1-Piperidinylacetamide, 4-[(2-methoxyphenyl)amino]-N-(2-pyridinyl)-
[CA INDEX NAME]





23 242360-27-7 CAROLUS
23 1-Piperidinylacetamide, 4-[(2-methoxyphenyl)amino]-N-(2-pyridinyl)-
hydrochloride (1:1) [CA INDEX NAME]



● 2 HCl
22 242360-28-9 CAROLUS
22 1-Piperidinylacetamide, 4-[(2-methoxyphenyl)amino]-N-(2-pyridinyl)-
hydrochloride (1:1) [CA INDEX NAME]

L5 ANSWER 21 OF 27 CAROLUS COPYRIGHT 2008 ACS on STN
1999-01313 - Nonsteroidal steroid tetracyclic sesquiterpenoid alkaline
derivatives as cardiovascular agents. Matsumae, Toshihiko; Kakefuda,
Akio; Kubota, Hidetaka; Maruda, Noriyuki [Tanabe Seiyaku Pharmaceutical Co.,
Ltd., Japan]. Jpn. Kokai Tokkyo Koho 29 11935072 A. 1999-01313. Sales 1, 16
pp. (Japanese). CODEN JPOAKA. APPGICNTRN. JP 1999-75446 199901324.

G2



A8 The title compds. 2 [X1, X2 = H, alkyl, etc.; X = O, S, etc.; A1 = alkylene; A2 = alkylene, or A2 may be nonoxatane; A3 = alkylene or A3 may be nonoxatane; ring B = [un]substituted hydrocarbon ring, etc.], useful as cardiovascular agents, have a pharmacological effect (no data), are prepared. For example, the title compound 21 was prepared

IT 245057-04-1P 245057-07-2P

(Pharmacological activity or effects, except adverse; ENU (bioassay))

study (unclassified); 2H (Synthetic preparation); TEC (Therapeutic use); study (unclassified); 2H (Preparation); TEC (Therapeutic use); study (unclassified); 2H (Preparation); TEC (Therapeutic use); (preparation of tetracyclic sesquiterpenoid alkaline derivative, as cardiovascular

agent)


RS 245057-04-1 CAROLUS

1-Piperidinylacetamide, 4-[(2-methoxy-2-(1H)-isoxazolyl)-3-(4-(2,4-dimethoxyphenyl)anilino)-1-piperidinyl]-, hydrochloride (1:1) [CA INDEX NAME]



● 2 HCl

RS 245057-07-2 CAROLUS



● 2 HCl

L5 ANSWER 22 OF 27 CAROLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 1-Phenyl-3-[(4-(1H)-3-benzoisoxazol-5-ylamino)-1-piperidinyl]-1-(3,4-dihydro-4,7-dimethoxy-2(1H)-isoxazolyl)-, hydrochloride (1:1) [CA INDEX NAME]




● 2 HCl



LS ANSWER TO 27 CARLOS COPYRIGHT 2008 ACS ON STN
1984-020558 Document No. 1011230558 Original Reference No.
1011230558-35202a

6-Aryl-1,4-dihydro-5(2H)-pyridazinone and their use. Kozly, Phillip A.;
Thyes, Marcel; Franke, Albrecht; Koenig, Horst; Lehmann, Hans Dieter;
Gries, Josef; Friedrich, Ludwig; Koenig, Dieter (BASF AG - G., Fed. Rep.
Ger.); Ger. Ofcnen. DE 330221 A1 19840726, 52 pp. (German). CODEN:
GMXXXX. APPLICATION DE 1983-352021 19830122.



10565979.trn

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 10:37:34 ON 08 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 5, 2008 (20081205/UP).

=>